(PharmaNewsWire.Com, July 26, 2017 ) Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1)-Angiopoietin-1 receptor or CD202B is a protein encoded by the TEK gene.It regulates angiogenesis endothelial cell survival proliferation migration adhesion and cell spreading reorganization of the actin cytoskeleton. It also maintains of vascular quiescence. It has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from blood vessels. It is required for normal angiogenesis and heart development during embryogenesis. It is required for post-natal hematopoiesis.
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.The molecules developed by companies in Pre-Registration Phase III Phase I and Preclinical stages are 1 1 2 and 4 respectively. Report covers products from therapy areas Oncology Metabolic Disorders Ophthalmology Cardiovascular and Male Health which include indications Glioblastoma Multiforme (GBM) Pancreatic Cancer Solid Tumor Bile Duct Cancer (Cholangiocarcinoma) Breast Cancer Colorectal Cancer Epithelial Ovarian Cancer Fallopian Tube Cancer Hepatocellular Carcinoma Metastatic Colorectal Cancer Peritoneal Cancer Relapsed Acute Myeloid Leukemia Soft Tissue Sarcoma Acute Myelocytic Leukemia (AML Acute Myeloblastic Leukemia) Adenoid Cystic Carcinoma (ACC) Adrenocortical Carcinoma (Adrenal Cortex Cancer) Bladder Cancer Chronic Myelocytic Leukemia (CML Chronic Myeloid Leukemia) Diabetic Foot Ulcers Diabetic Macular Edema Endometrial Cancer Erectile Dysfunction Gastric Cancer Gastrointestinal Stromal Tumor (GIST) Liver Cancer Lung Cancer Medullary Thyroid Cancer Melanoma Metastatic Brain Tumor Metastatic Breast Cancer Metastatic Renal Cell Carcinoma Myelodysplastic Syndrome Myelofibrosis Myocardial Infarction Neuroendocrine Tumors Non-Rhabdomyosarcoma Non-Small Cell Lung Cancer Ocular Melanoma Open-Angle Glaucoma Ovarian Cancer Pheochromocytoma Refractory Acute Myeloid Leukemia Refractory Multiple Myeloma Relapsed Multiple Myeloma Renal Cell Carcinoma Rhabdomyosarcoma Skin Cancer Transitional Cell Cancer (Urothelial Cell Cancer) Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Ureter Cancer Urethral Cancer Wet (Neovascular / Exudative) Macular Degeneration and Wilms' Tumor (Nephroblastoma) .
The latest report Angiopoietin 1 Receptor-Pipeline Review H2 2017 outlays comprehensive information on the Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type. It also reviews key players involved in Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.
- The report provides a snapshot of the global therapeutic landscape for Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - The report reviews Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities - The report reviews key players involved in Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics
- Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles Aerpio Therapeutics Inc Bayer AG Deciphera Pharmaceuticals LLC Exelixis Inc PharmAbcine Inc Q BioMed Inc
List of Tables Number of Products under Development by Stage of Development H2 2017 Number of Products under Development by Therapy Areas H2 2017 Number of Products under Development by Indications H2 2017 Number of Products under Development by Indications H2 2017 (Contd..1) H2 2017 Number of Products under Development by Indications H2 2017 (Contd..2) H2 2017 Number of Products under Development by Companies H2 2017 Products under Development by Companies H2 2017 Products under Development by Companies H2 2017 (Contd..1) H2 2017 Products under Development by Companies H2 2017 (Contd..2) H2 2017 Products under Development by Companies H2 2017 (Contd..3) H2 2017 Number of Products by Stage and Mechanism of Actions H2 2017 Number of Products by Stage and Route of Administration H2 2017 Number of Products by Stage and Molecule Type H2 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
